Alnylam Pharmaceuticals, INC Form 4 insider transactions

Alnylam Pharmaceuticals' CFO, Jeffrey V. Poulton, sold a portion of his shares following the vesting of a performance-based stock unit, triggered by a positive clinical trial result.

Alnylam Pharmaceuticals' EVP, Chief Commercial Officer, Tolga Tanguler, sold shares to cover tax obligations after a performance-based stock unit vested.

Alnylam Pharmaceuticals' CSO and EVP, Kevin Fitzgerald, sold a significant number of shares following the vesting of a performance-based stock unit.

Pushkal Garg, CMO & EVP of Development & Medical Affairs at Alnylam Pharmaceuticals, received 96 shares of common stock as a recognition for 10 years of continuous employment.

Robert W. Hesslein, EVP, CLO and Secretary of Alnylam Pharmaceuticals, acquired 7,245 shares of common stock through restricted stock units (RSUs) on October 1, 2024.

Alnylam Pharmaceuticals CEO Yvonne Greenstreet exercised stock options and sold 15,000 shares of common stock on August 20, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Kevin Fitzgerald, CSO & EVP, Head of Research at Alnylam Pharmaceuticals, reported the sale of common stock and exercise of stock options on August 12, 2024, according to a Form 4 filing.

Director Dennis Ausiello exercised stock options and sold shares of Alnylam Pharmaceuticals under a pre-arranged Rule 10b5-1 trading plan.

Alnylam Pharmaceuticals CEO Yvonne Greenstreet exercised stock options and sold shares of common stock on August 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Alnylam Pharmaceuticals CEO Yvonne Greenstreet sold 7,093 shares of common stock on July 11, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Amy Schulman exercised stock options and sold shares of Alnylam Pharmaceuticals under a pre-arranged Rule 10b5-1 trading plan.

Director David E.I. Pyott exercised stock options and sold shares of Alnylam Pharmaceuticals common stock on June 24, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Following the vesting of performance-based stock units due to positive clinical trial results, Alnylam's CMO & EVP of Development and Medical Affairs, Pushkal Garg, sold shares to cover tax obligations.

Alnylam Pharmaceuticals' CEO, Yvonne Greenstreet, reports acquisition and disposal of company stock following the vesting of performance-based stock units (PSUs) and subsequent sell-to-cover transactions.

Following the vesting of performance-based stock units due to positive clinical trial results, Alnylam's CFO, Jeffrey Poulton, sold shares to cover tax obligations.

Alnylam's EVP, Chief Commercial Officer Tolga Tanguler, reports acquisition of shares from performance-based stock units (PSU) and subsequent sales to cover tax obligations.

Alnylam CSO Kevin Fitzgerald reports the sale of company stock to cover tax obligations after a performance-based stock unit (PSU) vested due to positive clinical trial results.

Director Amy Schulman exercised stock options and sold shares of Alnylam Pharmaceuticals under a pre-arranged Rule 10b5-1 trading plan.

Director David E.I. Pyott acquired 5,228 stock options in Alnylam Pharmaceuticals on May 16, 2024, according to a Form 4 filing.

Director Peter Kellogg acquired stock options in Alnylam Pharmaceuticals, Inc. on May 16, 2024.

Director Carolyn R. Bertozzi acquired 5,228 stock options in Alnylam Pharmaceuticals, Inc. on May 16, 2024.

Director Charles Elliott Sigal reports acquisition of 5,228 shares of Alnylam Pharmaceuticals via stock option grant.

Director Olivier Brandicourt reports the acquisition of stock options in Alnylam Pharmaceuticals.

Director Margaret A. Hamburg acquired 5,228 stock options in Alnylam Pharmaceuticals, Inc. on May 16, 2024.

Director Colleen F. Reitan reports the acquisition of stock options in Alnylam Pharmaceuticals.

Director Michael W. Bonney reports acquisition of stock options in Alnylam Pharmaceuticals.

Director Amy Schulman acquired 5,228 stock options in Alnylam Pharmaceuticals on May 16, 2024.

Director Dennis Ausiello reports the acquisition of stock options in Alnylam Pharmaceuticals.

Director Phillip A. Sharp acquired 5,228 stock options in Alnylam Pharmaceuticals on May 16, 2024.

Tolga Tanguler, EVP and Chief Commercial Officer of Alnylam Pharmaceuticals, reports the acquisition of stock options and restricted stock units (RSUs) in a recent Form 4 filing.